Trial Profile

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Mitoxantrone (Primary) ; Navitoclax (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions

Most Recent Events

13 Aug 2024 Planned initiation date changed from 15 May 2024 to 31 Aug 2024.
13 Aug 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
10 Apr 2024 Planned initiation date changed from 15 Mar 2024 to 15 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com